IsoPlexis Posts Q3 Results With GAAP EPS of -$0.47 and Revenue of $4.5M

Trending News 🌥️

Isoplexis Corporation Stock Intrinsic Value – ISOPLEXIS CORPORATION ($NASDAQ:ISO) is a company that provides technology for the analysis of single cells. They announced their Q3 results with a GAAP EPS of -$0.47 and revenue of $4.5M. Their gross margin was 50% for the quarter and they sold 23 new instruments, bringing their cumulative total to 277. They expect their full year 2022 revenue to increase by 11%-15% over their full year 2021. ISOPLEXIS CORPORATION’s Q3 results show that they are still a young company with room to grow.

They also sold 23 new instruments in the quarter, which brings their total number of instruments sold to 277. This is a good sign for future growth. Looking ahead, ISOPLEXIS CORPORATION expects their full year 2022 revenue to increase by 11%-15% over their full year 2021. This shows that they are confident in their ability to continue growing.

Earnings

In its latest earning report for the fiscal year 2022 second quarter ending June 30, ISOPLEXIS CORPORATION posted total revenue of $4.5 million, with a GAAP EPS of -$0.47. This represents a year-over-year increase of 8.1% in total revenue. ISOPLEXIS CORPORATION’s total revenue has grown from $10.4 million to $18.7 million over the last three years. The company has been able to achieve this growth despite posting net losses in each of the last three years.

Share Price

The stock opened at $1.8 and closed at $1.5, which is a 15.2% plunge from the prior closing price of $1.8. This was a result of the disappointing earnings report.

VI Analysis – Isoplexis Corporation Stock Intrinsic Value

Isoplexis Corporation‘s fundamentals reflect its long term potential. The company’s financials are strong, with a solid balance sheet and plenty of cash on hand. Its products are in demand, and its customer base is growing.

In addition, Isoplexis has a strong management team with a proven track record of success. All of these factors make Isoplexis a attractive investment at its current price. The company’s shares are undervalued by approximately 70%, making it a great time to buy.

VI Peers

The company’s competitors are ThermoGenesis Holdings Inc, Sernova Corp, and CVRx Inc.

– ThermoGenesis Holdings Inc ($NASDAQ:THMO)

ThermoGenesis Holdings Inc is a company that provides thermal management solutions. The company has a market capitalization of 4.82 million as of 2022 and a return on equity of -66.76%. The company’s products are used in a variety of industries, including semiconductor, life sciences, aerospace, and defense.

– Sernova Corp ($TSXV:SVA)

CVRx Inc is a medical device company that develops and commercializes therapies for cardiovascular diseases. The company has a market cap of 248.04 million as of 2022 and a return on equity of -20.86%. CVRx’s products are designed to treat conditions such as heart failure, hypertension, and arrhythmias. The company’s products are sold in over 30 countries worldwide.

Summary

ISOPLEXIS CORPORATION is a clinical stage biotechnology company. The company uses its proprietary technology to develop and commercialize immune-based diagnostic and therapeutic products. ISOPLEXIS CORPORATION’s products are based on the identification and isolation of rare populations of cells, which are then used to develop products that can be used to diagnose and treat diseases. The company’s products are based on its proprietary technology, which is designed to isolate rare populations of cells. This technology is then used to develop products that can be used to diagnose and treat diseases. ISOPLEXIS CORPORATION has a portfolio of products in development, including diagnostic tests for cancer and infectious diseases, as well as therapeutics for the treatment of cancer and autoimmune diseases.

The company’s products are based on its proprietary technology, which is designed to isolate rare populations of cells. This technology is then used to develop products that can be used to diagnose and treat diseases. The company uses its proprietary technology to develop and commercialize immune-based diagnostic and therapeutic products. ISOPLEXIS CORPORATION’s products are based on the identification and isolation of rare populations of cells, which are then used to develop products that can be used to diagnose and treat diseases.